GlassScriptPhysician profile
Phong Huy Bui
NPI 1316177462
$9,604.97
in general payments reported to CMS, 2019-2025
36 companies · $1,617 in 2025
The $1,617 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,012 · 2020: $443 · 2021: $1,067 · 2022: $1,514 · 2023: $1,617 · 2024: $1,335 · 2025: $1,617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,432 · Education: $136 · Travel and Lodging: $1.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,431.84 |
| Education | $136.36 |
| Travel and Lodging | $1.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,746.72 | 2019-2025 | Mounjaro, Trulicity, Jardiance |
| Novo Nordisk INC | $1,444.73 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $1,178.19 | 2020-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $958.48 | 2019-2025 | Jardiance, Synjardy |
| Dexcom, INC. | $720.78 | 2019-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $639.55 | 2019-2024 | Farxiga |
| Amgen INC. | $460.73 | 2019-2025 | Evenity, Tepezza, Prolia |
| Sanofi-Aventis U.S. LLC | $318.18 | 2019-2025 | |
| Abbott Laboratories | $300.94 | 2019-2025 | Freestyle Libre 3 |
| Mannkind Corporation | $185.39 | 2024-2025 | |
| Amarin Pharma, INC. | $169.96 | 2019-2021 | |
| Insulet Corporation | $152.70 | 2019-2024 | Omnipod |
| Janssen Pharmaceuticals, INC | $136.13 | 2019-2020 | |
| Becton, Dickinson and Company | $125.41 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.60 | 2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $120.24 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $117.36 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $73.65 | 2021-2024 | Minimed 780g |
| Alvogen INC | $72.49 | 2023-2025 | Teriparatide |
| Merck Sharp & Dohme LLC | $68.12 | 2019 | |
| Medtronic Minimed, INC. | $60.94 | 2019 | |
| Novartis Pharmaceuticals Corporation | $57.67 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $44.00 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Cequr Corporation | $40.14 | 2022-2023 | Cequr Simplicity |
| Radius Health, INC. | $39.61 | 2021-2022 | |
| Ascendis Pharma Endocrinology INC | $28.01 | 2025 | Yorvipath |
| Sequel Med Tech, LLC | $27.68 | 2025 | Twiist |
| Recordati_rare_diseases_inc. | $26.57 | 2023 | Signifor Lar, Isturisa |
| Rhythm Pharmaceuticals, INC. | $26.05 | 2025 | Imcivree |
| Ultragenyx Pharmaceutical INC. | $24.98 | 2022 | |
| Embecta Corp. | $24.63 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Bigfoot Biomedical INC | $23.09 | 2022 | |
| Valeritas, INC. | $19.12 | 2019 | |
| Beta Bionics, INC. | $16.50 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Ascensia Diabetes Care US INC. | $16.24 | 2024 | |
| Madrigal Pharmaceuticals | $15.39 | 2025 | Rezdiffra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phong Bui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.